Therapeutics News

Aldeyra Therapeutics has enrolled the first patient in a phase 3 clinical trial designed to allow possible resubmission of the new drug application of topical 0.25% reproxalap for dry eye disease, according to a company press release.

Qlaris Bio raised $24 million during series B financing for the clinical development of QLS-111, a new IOP-lowering drug candidate for patients with glaucoma, the company announced in a press release.

Ocugen has announced that dosing is complete in the second cohort of its phase 1/2 ArMaDa clinical trial to assess the safety of OCU410, a modifier gene therapy candidate for geographic atrophy.

Oral minocycline was not associated with a reduction in geographic atrophy enlargement over 24 months vs. a 9-month run-in period among patients with age-related macular degeneration, according to a study in JAMA Ophthalmology.

Ocuphire Pharma has enrolled the first patient in its LYNX-2 phase 3 registration study of phentolamine ophthalmic solution 0.75% for treatment of reduced visual acuity under low-light conditions after keratorefractive surgery.

Okyo Pharma has announced additional findings from its phase 2 trial of OK-101, including statistically significant improvement in ocular pain relief, conjunctival staining and tear breakup time in patients with dry eye disease.

NEW YORK — Optometrists may be the first to recognize adverse effects of systemic medications, which warrants collaboration with the prescribing physician, Jessica Steen, OD, FAAO, Dipl ABO, said at Vision Expo East.

Brassica Pharma has initiated a voluntary recall of its eye ointment products after an FDA inspection of a Brassica facility found a “lack of sterility assurance.”

ATLANTA — A long-term study of Vevye for treating dry eye showed an improvement in Schirmer’s scores by 98% at week 46, according to Walter O. Whitley, OD, MBA, FAAO.

Skye Bioscience has completed enrollment for its phase 2a trial of SBI-100, a cannabinoid receptor type 1 agonist being developed for patients with primary open-angle glaucoma or ocular hypertension, according to a company press release.